GlassScriptPhysician profile
Christopher S Calder
NPI 1386693596
$3,263.07
in general payments reported to CMS, 2019-2025
37 companies · $627 in 2025
The $627 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $179 · 2021: $560 · 2022: $559 · 2023: $438 · 2024: $479 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526 · Education: $17.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,526.47 |
| Education | $17.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $345.41 | 2021-2025 | |
| Ucb, INC. | $285.15 | 2019-2025 | Zilbrysq |
| Allergan, INC. | $270.15 | 2019-2021 | |
| Abbvie INC. | $259.65 | 2021-2025 | Ubrelvy, Qulipta |
| Csl Behring | $238.60 | 2021-2023 | Hizentra, Privigen |
| Alexion Pharmaceuticals, INC. | $175.99 | 2019-2025 | Ultomiris |
| Genzyme Corporation | $137.65 | 2020-2023 | |
| Lundbeck LLC | $132.21 | 2022-2025 | Vyepti |
| Sk Life Science, INC. | $130.95 | 2022-2025 | Xcopri |
| Pfizer INC. | $121.51 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $97.40 | 2023-2025 | |
| Amgen INC. | $91.12 | 2021-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $90.90 | 2022-2025 | Nuplazid |
| Argenx US, INC. | $87.24 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Genentech USA, INC. | $84.83 | 2022-2025 | Ocrevus, Ocrevus Zunovo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $72.30 | 2022-2025 | |
| Livanova USA, INC. | $59.54 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $54.78 | 2021 | |
| Upsher-Smith Laboratories LLC | $49.74 | 2022 | |
| Biogen, INC. | $49.61 | 2021-2023 | Tysabri |
| Neurocrine Biosciences, INC. | $49.25 | 2021-2025 | |
| Grifols USA, LLC | $45.17 | 2019-2025 | Gamunex-C |
| Janssen Pharmaceuticals, INC | $40.08 | 2019-2022 | |
| Celgene Corporation | $39.83 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $39.71 | 2022-2023 | Austedo |
| Neurelis, INC. | $33.78 | 2024-2025 | Valtoco |
| Emd Serono, INC. | $29.59 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $24.09 | 2025 | Rexulti |
| Sarepta Therapeutics, INC. | $22.99 | 2019 | |
| Averitas Pharma INC. | $16.90 | 2024 | Qutenza |
| Tanabe Pharma America, INC. | $16.12 | 2019 | |
| Tg Therapeutics, INC. | $15.93 | 2025 | |
| Lilly USA, LLC | $15.28 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $14.72 | 2024 | Wainua |
| Biohaven Pharmaceutical Holding Company LTD. | $12.48 | 2022 | |
| Medtronic USA, INC. | $12.42 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Calder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.